Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
John Laffey, University College Hospital Galway
ClinicalTrials.gov Identifier:
NCT01482650
First received: November 25, 2011
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

The investigators have performed a number of studies on novel airway devices, including an observational study on the performance of a new supraglottic airway named Baska mask. In this new proposed study the investigators would like to compare directly,in a randomized clinical trial, this device with the device the investigators routinely use - the single use laryngeal mask airway - LMA, in female patients undergoing general anaesthesia.

This study will determine which device performs best, as measured by key parameters (insertion success rate, seal pressures, time to and ease of insertion, failure rate, complications etc) as regarding the performance and safety profile of the Baska mask and the LMA.

The investigators have two study hypotheses, namely (1) non-inferiority of first placement attempt success rate of Baska vs LMA; and (2) greater seal pressure of the Baska mask vs LMA.

A number of secondary endpoints will be monitored and analyzed (time to and ease of insertion, failure rate, complications etc).


Condition Intervention Phase
Performance and Safety of an Airway Management Device
Device: supraglottic airway placement and use
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Comparison of the Effectiveness of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients

Further study details as provided by University College Hospital Galway:

Primary Outcome Measures:
  • Rate of successful placement of the supraglottic device on first attempt [ Time Frame: Within 30minutes of commencement of general anaesthesia ] [ Designated as safety issue: No ]
    The hypothesis is that the BASKA mask will have first placement attempt success rate that is no more than 20% less than that of the single use LMA device.

  • Seal pressure of the supraglottic device [ Time Frame: Within 30minutes of commencement of general anaesthesia, immediately after successful placement is accomplished. ] [ Designated as safety issue: No ]
    The investigators will measure the airway seal provided by the device used. The hypothesis is that the seal pressure with the BASKA mask will be 40% higher than that of the single use LMA.


Secondary Outcome Measures:
  • Overall rate of successful placement of the supraglottic device [ Time Frame: Within 30minutes of commencement of general anaesthesia. Up to 3 device placement attempts are allowed. ] [ Designated as safety issue: No ]
  • Number of device placement attempts [ Time Frame: Within 30minutes of commencement of general anaesthesia ] [ Designated as safety issue: No ]
  • User - rated Ease of insertion of the device [ Time Frame: Within 30minutes of commencement of general anaesthesia ] [ Designated as safety issue: No ]
    the investigators will use 10cm visual analogue scale

  • vital parameters stability [ Time Frame: In the period immediately before and during the first 35 minutes of the general anaesthesia ] [ Designated as safety issue: No ]
    The investigators will record noninvasive arterial oxygen saturation, heart rate and blood pressure preoperatively, after anaesthesia is induced and after the airway is placed.

  • Laryngeal view obtained on fiberoptic assessment [ Time Frame: within 2hours of commencement of general anaesthesia ] [ Designated as safety issue: No ]
    The investigators will perform this where feasible.

  • User rated Ease of removal of the device [ Time Frame: At the time of device removal (usually within 15 minutes before or after the end of the general anaesthesia) ] [ Designated as safety issue: No ]
    The investigators will use 10cm visual analogue scale

  • Complication rates [ Time Frame: from the moment general anaesthesia commenced up to 3 days postoperatively ] [ Designated as safety issue: Yes ]

    Complications specifically monitored will be: blood staining, laryngospasm, lip damage, pain, dysphagia, dysphonia.

    The investigators will record other complications related to the use of the device, including but not limited to: desaturation episodes, loss of airway with need to manipulate mask/switch to alternative device, teeth damage, regurgitation, aspiration


  • Duration of successful insertion attepts [ Time Frame: Within 30 minutes of commencement of general anaesthesia ] [ Designated as safety issue: No ]
    This outcome measure is defined as the period from the time device touched until successfull ventilation is achieved as per protocol.


Enrollment: 92
Study Start Date: November 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Baska mask Device: supraglottic airway placement and use
The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
Active Comparator: single use laryngeal mask airway (LMA) Device: supraglottic airway placement and use
The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.

Detailed Description:

Airway management is essential component of the safe and efficient provision of general anaesthesia. Supraglottic airway devices have established place in the airway management.

The Baska mask is a new supraglottic airway device. It bears many of the features of the industry standard - the laryngeal mask airway (LMA), with few potential improvements:

  • The cuff is not pressurized thus reducing the risk of oropharyngeal tissue damage.
  • Improved cuff seal during the inspiratory phase of positive pressure ventilation which may reduce leak and make ventilation more efficient.
  • An improved system for drainage of oropharyngeal contents intended to reduce the rate of lung aspiration.
  • The Baska mask is inserted in neutral head position thus reducing the need for neck manipulation.
  • There is integrated bite-block to reduce the risk of patients biting and blocking the airway.

The results from the observational study of the performance of the Baska mask are promising and the investigators feel a randomized comparative study against the gold standard device, the Laryngeal Mask Airway (LMA) is justified.

This study is a randomized, single blinded, controlled clinical trial. The participants will be allocated to two groups, in which the investigators will use either a single use LMA device or the Baska mask (single use).

Clinical Research Ethics Committee approval has been obtained. Suitable participants will be recruited after written informed consent and screened for inclusion and exclusion criteria.

Standard anaesthetic preassessment and anaesthesia will be provided.

Consenting patients will be randomly allocated to either of the 2 study groups.

Protocol for airway size selection and attempts at placement will be followed.

The investigators will monitor a number of parameters, including time and ease of insertion, airway seal pressure, airway leak, complications, haemodynamic and ventilatory parameters, ease of removal and other.

Follow up will be performed.

The investigators have two primary hypotheses:

  1. That the BASKA mask will have an insertion success rate that is no more than 20% less than that of the single use LMA device.
  2. That the seal pressure with the BASKA mask will be 40% higher than that of the single use LMA.

In addition to the above the investigators will evaluate a number of secondary outcomes.

  Eligibility

Ages Eligible for Study:   16 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female
  • Written informed consent
  • ASA 1-3
  • No relevant allergies
  • Body-mass index (BMI) 20-35
  • Age 16-85
  • Non-urgent surgery of planned duration 0.25-4 hrs

Exclusion Criteria:

  • Inability of patient/parent to understand or consent for the trial
  • Neck pathology
  • Previous or anticipated problems with the upper airway or upper GI tract (reflux, hiatus hernia, oropharyngeal tumour, upper respiratory tract infection in the last 10 days)
  • BMI >35
  • Predicted or previously documented difficult airway
  • Live Pregnancy
  • Increased risk for Gastric Aspiration
  • Current participation in another Clinical Study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01482650

Locations
Ireland
Galway University Hospitals
Galway, Ireland
Sponsors and Collaborators
University College Hospital Galway
Investigators
Principal Investigator: John Laffey, FFARCSI National University of Ireland, Galway, and Galway University Hospitals
  More Information

No publications provided

Responsible Party: John Laffey, Professor of Anaesthesia and Critical Care, Consultant Anaesthetist, University College Hospital Galway
ClinicalTrials.gov Identifier: NCT01482650     History of Changes
Other Study ID Numbers: C.A. 650
Study First Received: November 25, 2011
Last Updated: June 18, 2012
Health Authority: Ireland: Research Ethics Committee

Keywords provided by University College Hospital Galway:
Baska mask
LMA
laryngeal mask airway
supraglottic airway device

ClinicalTrials.gov processed this record on November 20, 2014